
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrated strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which represents a 105% increase quarter-over-quarter, alongside a notable improvement in gross margins to 60.3%. The sequential sales recovery indicates that previous challenges were likely temporary, suggesting a potential for sustained growth. Additionally, the company's strategic move to enter into a non-binding merger agreement with Applied Digital Cloud may enhance its market position and drive further expansion in both the healthcare and industrial sectors.
Bears say
The financial analysis reveals a concerning trend for Ekso Bionics Holdings, as the company's recent revenue performance fell short of expectations, leading to notable order delays from enterprise sales that negatively impacted topline growth by $1.5 million. Additionally, the company reported a net loss of $0.54 per share in the third quarter of 2025, albeit an improvement compared to consensus estimates, which indicates persistent challenges in achieving profitability. This combination of missed revenue targets and ongoing operational weaknesses has prompted analysts to downgrade the company's stock outlook, reflecting a cautious sentiment about its financial future.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares